drugset / Trial / NCT02982395
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.
Timeline
- Start
- 2017-01
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel-PM | Unknown | 75 mg | Other |
| Comparator | Mitomycin C | Other / unclassified | 40 mg | Other |